|Year : 2014 | Volume
| Issue : 6 | Page : 644-648
Effect of adrenergic blockers, carvedilol, prazosin, metoprolol and combination of prazosin and metoprolol on paracetamol-induced hepatotoxicity in rabbits
Maysaa B Zubairi1, Jawad H Ahmed2, Sawsan S Al-Haroon3
1 College of Pharmacy, Department of Pharmacology and Toxicology, Basrah College of Medicine, Basrah, Iraq
2 Department of Pharmacology, Basrah College of Medicine, Basrah, Iraq
3 Department of Pathology and Forensic Medicine, Basrah College of Medicine, Basrah, Iraq
|Date of Submission||27-Jan-2014|
|Date of Decision||28-Apr-2014|
|Date of Acceptance||13-Oct-2014|
|Date of Web Publication||18-Nov-2014|
Jawad H Ahmed
Department of Pharmacology, Basrah College of Medicine, Basrah
Source of Support: None, Conflict of Interest: None
Objectives: To evaluate hepatoprotective potential of carvedilol, prazosin, metoprolol and prazosin plus metoprolol in paracetamol-induced hepatotoxicity.
Materials and Methods : Thirty-six male rabbits were divided into six groups, six in each, group 1 received distilled water, group 2 were treated with paracetamol (1 g/kg/day, orally), group 3, 4,5 and 6 were treated at a dose in (mg/kg/day) of the following: Carvedilol (10 mg), prazosin (0.5 mg), metoprolol (10 mg), and a combination of metoprolol (10 mg) and prazosin (0.5 mg) respectively 1 h before paracetamol treatment. All treatments were given for 9 days; animals were sacrificed at day 10. Liver function tests, malondialdehyde (MDA) and glutathione (GSH) in serum and liver homogenates were estimated. Histopathological examinations of liver were performed.
Results: Histopathological changes of hepatotoxicity were found in all paracetamol-treated rabbits. The histopathological findings of paracetamol toxicity disappeared in five rabbits on prazosin, very mild in one. In carvedilol group paracetamol toxicity completely disappeared in three, while mild in three rabbits. Paracetamol hepatotoxicity was not changed by metoprolol. In metoprolol plus prazosin treated rabbits, moderate histopathological changes were observed. Serum liver function tests and MDA in serum and in liver homogenate were elevated; GSH was depleted after paracetamol treatment and returned back to the control value on prior treatment with prazosin. MDA in serum and liver homogenate, alkaline phosphatase, total bilirubin were significantly decreased after carvedilol and prazosin plus metoprolol treatments.
Conclusion : Carvedilol and prazosin are hepatoprotective in paracetamol hepatotoxicity, combination of prazosin and metoprolol have moderate, and metoprolol has a little hepatoprotection.
Keywords: Antioxidant, carvedilol, liver toxicity, metoprolol, paracetamol, prazosin
|How to cite this article:|
Zubairi MB, Ahmed JH, Al-Haroon SS. Effect of adrenergic blockers, carvedilol, prazosin, metoprolol and combination of prazosin and metoprolol on paracetamol-induced hepatotoxicity in rabbits
. Indian J Pharmacol 2014;46:644-8
|How to cite this URL:|
Zubairi MB, Ahmed JH, Al-Haroon SS. Effect of adrenergic blockers, carvedilol, prazosin, metoprolol and combination of prazosin and metoprolol on paracetamol-induced hepatotoxicity in rabbits
. Indian J Pharmacol [serial online] 2014 [cited 2021 Jun 13];46:644-8. Available from: https://www.ijp-online.com/text.asp?2014/46/6/644/144937
| » Introduction|| |
Paracetamol is a widely used over-the-counter analgesic and antipyretic with a documented potential to damage the liver. In the United States and Great Britain, approximately one-half of all cases of acute liver failure is attributed to paracetamol toxicity.  It has been found in a model of paracetamol-induced hepatotoxicity in rats that there is an association between paracetamol hepatotoxicity and raised plasma levels of catecholamine.  and that alpha-adrenergic blockers such as prazosin, doxazosin and terazosin demonstrated a hepatoprotective effect that is attributed to inhibition of elevated catecholamine.  The present study was designed to investigate the possible protective effects of carvedilol, metoprolol, prazosin in paracetamol induced hepatotoxicity in rabbits.
| » Materials and Methods|| |
Preparation of Drugs
Paracetamol: 30 tablets of paracetamol (500 mg, GlaxoSmithKline, United Kingdom) were grinded by porcelain mortar, dissolved in 60 ml of distilled water to obtain a suspension with a concentration of (250 mg/ml). An accurate dose of (1 g/kg) was administered orally for each rabbit by a pediatric nasogastric tube introduced through a hole in wood tongue depressor placed between the teeth to prevent the rabbit chewing the tube.
Five tablets of carvedilol (12.5 mg, Roche, Switzerland) were grinded by porcelain mortar; dissolved in 10 ml distilled water to obtain a solution concentration of (6.25 mg/ml), then it was given in a dose of (10 mg/kg) orally.
Two tablets of prazosin (5 mg, Pfizer, USA) were grinded, dissolved in 20 ml distilled water to obtain a suspension concentration of (0.5 mg/ml), and each rabbit received (0.5 mg/kg) orally.
Two tablets of metoprolol (50 mg, AstraZeneca, Switzerland) were grinded, dissolved in 20 ml distilled water to obtain a suspension concentration of (5 mg/ml) and given to each rabbits in a dose of (10 mg/kg) orally.
The experiments were carried out on 36 locally bred sexually mature domestic male rabbits. Their body weights ranged from 1 to 2 kg. The animals were housed in the main animal house at Basrah College of medicine. They were kept in a stainless steel cage for acclimatization with a 12:12-h light/dark cycle and free access to food and drinking water. They were not fed for 12 h before the experiment.
The study protocol was approved by the local institutional Ethical Committee. The study was carried out between November 2012 and April 2013.
The rabbits were randomly divided into six groups, six animals in each group. Group 1 (control group), were treated with distilled water 2 ml daily for 9 days. Group 2 (paracetamol toxicity group) were treated with a single loading dose of paracetamol (1 g/kg/day, orally) for 9 days. Group 3 were pretreated with carvedilol (10 mg/kg/day, orally) once daily 1 h before paracetamol treatment. Carvedilol and paracetamol treatment were continued for 9 days. Groups 4, 5 and 6 followed the same treatment protocol of group 3 but treated with prazosin (0.5 mg/kg/day, orally), metoprolol (10 mg/kg/day, orally), and the combination of prazosin and metoprolol at the same doses for individual drugs.
Blood Sampling and Tissue Handling
On the morning of day 10, 5-10 ml of blood was taken directly from the heart under light ether anesthesia, and transferred into non heparinized tube and allowed for few minutes to clot. Serum was separated by centrifugation at 3000 rpm for 20 min. One ml of serum was used freshly to measure serum malondialdehyde (MDA) while the rest of the serum was frozen at −20°C for the analysis of liver function test and glutathione (GSH) measurements. The rabbits were then sacrificed; liver specimens were obtained for the biological measurements and histopathological examination.
The specimens were examined by a specialist histopathologist (argininosuccinate synthetase) at the Department of Pathology and Forensic Medicine, Basrah College of Medicine. The examiner was blinded for the treatments.
Preparation of Liver Homogenate
Liver tissues were homogenized in cold phosphate buffer saline (potential of hydrogen = 7.4) to obtain 10% of liver homogenate (using Hiedolph electrical homogenizer, Korea) at 6000 rpm for 20 min.
Estimation of serum malondialdehyde
Thiobarbituric acid assay of Buege and Aust (1978)  was used for measuring serum MDA.
Estimation of malondialdehyde in liver homogenates
Malondialdehyde levels in liver homogenates were estimated as described by Ohkawa et al., 1979. 
Estimation of glutathione in serum and liver homogenate
Enzyme-linked immunosorbent assay method was used for quantitative determination of endogenous GSH concentrations in serum and in liver homogenate using kit specific for rabbits (Cusabio reagents, Cusabio laboratories, Daxueyuan Road, Donghu Hi-Tech development area, Wuhan, China).
Liver Function Tests
The activities of serum aspartate aminotransferase (S. AST) and serum alanine aminotransferase (S. ALT) were estimated using commercially available kits (Randox diagnostic reagents, Randox Laboratories, United Kingdom). Serum alkaline phosphatase (S. ALP) and serum total bilirubin were estimated by commercially available kits (Biolabo reagents, Biolabo SA, France).
Statistical Package for the Social Sciences computer package version 19 (SPSS Inc. Chicago; USA; availble form: http:www.spss.com) was used for statistical analysis. Data were analyzed by one-way analysis of variance. Tukey Honestly Significant Difference test was used to compare between the means. The results were considered significant at P < 0.05. The results were expressed as mean ± standard deviation, unless otherwise stated.
| » Results|| |
The control group
There were no histopathological changes in all liver samples obtained from rabbits in this group (n = 6). A representative histopathological slide is presented in [Figure 1]a.
|Figure 1: (a) A healthy liver tissue from a rabbit on distilled water (group 1), clear portal area, portal or hepatic vein and bile duct are observed (H and E, power ×10). (b) A liver tissue from a rabbit treated with paracetamol (group 2). Portal inflammation around the bile duct and portal vein, sinusoidal dilatation also detected (H and E, power ×40). (c) A liver tissue from a rabbit receiving carvedilol followed by paracetamol (group 3), the hepatic vein, central vein and the surrounding area appear normal only with mild sinusoidal dilatation (H and E, power ×10)|
Click here to view
The histopathological changes of moderate to severe hepatotoxicity were seen in all rabbits in this group and summarized as follows [Figure 1]b:
- Perivenular necrosis and degeneration of hepatocytes extending to the mid zonal area
- Sinusoidal dilatation with congestion (lobular and portal) profound accumulation of erythrocytes within the sinusoids
- Clear inflammation represented by lymphocytic infiltration (portal and lobular)
- Moderate to severe portal inflammatory cell infiltration.
Carvedilol + paracetamol group
In three rabbits, the liver appears completely normal, in two rabbits the liver showed only mild sinusoidal dilatation, and one rabbit with mild inflammatory cell infiltration of lymphocytes in the portal area [Figure 1]c.
Prazosin + paracetamol group
Histopathological examination showed disappearance of paracetamol toxicity in five rabbits pretreated with prazosin. Mild perivenular sinusoidal dilatation was seen in one rabbit.
Metoprolol + paracetamol group
In three rabbits, the liver showed hydropic degeneration ranged from diffuse to mild and perivenular sinusoidal dilatation, two rabbits with mild portal inflammation and sinusoidal dilatation and in one rabbit only sinusoidal dilatation was observed [Figure 2]a and b.
|Figure 2: (a) A liver tissue from a rabbit on metoprolol and paracetamol (group 5), shows lymphocytic infiltration (portal inflammation around the bile duct and sinusoidal dilatation (H and E, power ×40). (b) A liver tissue from a rabbit on metoprolol and paracetamol, hydropic degeneration around the central vein is observed (H and E, power ×40). (c) A liver tissue from a rabbit on prazosin, metoprolol and paracetamol (group 6), shows portal area inflammation, central vein, bile duct and sinusoidal dilatation (H and E, power ×40)|
Click here to view
Prazosin + metoprolol + paracetamol group
Mild perivenular sinusoidal dilatation and mild inflammatory cell infiltration only in the portal area observed in four rabbits and two rabbits developed mild perivenular sinusoidal dilatation without inflammation [Figure 2]c.
Effect of Treatments on Serum Liver Enzymes
Effect on serum aspartate aminotransferase
Treatment with paracetamol has resulted in a significant rise in AST level to 31 ± 8.06 U/I compared with11.5 ± 3.14 U/I in the control group (P < 0.03). The rise by paracetamol in AST was significantly decreased by pretreatment with prazosin to 12.3 ± 2.87 U/I, P < 0.03. In the same direction, pretreatment with carvedilol reduced AST level to 14.6 ± 5.57 U/I which is-marginally significant, P = 0.06. While pretreatment with metoprolol or with prazosin plus metoprolol produced less reduction in the mean AST level to 19.3 ± 10.38 and 19.6 ± 9.64 U/I respectively, which is statistically not significant, P > 0.14. The data are presented in [Table 1].
|Table 1: The Effect of adrenergic blockers on liver enzymes and total bilirubin in paracetamol-induced hepatotoxicity in rabbits|
Click here to view
Effect on serum alanine aminotransferase
Treatment with paracetamol has resulted in a significant elevation in the level of ALT from 6.5 ± 1.87 U/me in the control group to 15.8 ± 8.23 U/me, P < 0.01. Pretreatment with carvedilol reduced ALT to 10.1 ± 7.33 U/I, this reduction did not achieve statistical significance. Pretreatment with prazosin has significantly reduced ALT toward the control value (7.16 ± 2.99 U/I), P < 0.01. A small and insignificant reduction in ALT (12.8 ± 8.75 U/I) was observed with pretreatment with metoprolol. There was a marginally significant reduction in ALT level to 10.1 ± 4.3 U/I in the group pretreated with the combination prazosin and metoprolol, P = 0.07 [Table 1].
Effect on serum alkaline phosphatase
Serum ALP level in the control group was 38.2 ± 20.5 IU/L, which was significantly increased by paracetamol treatment to 75.4 ± 27 IU/L and then significantly reduced in the groups pretreated with carvedilol, prazosin, metoprolol and the combination metoprolol and prazosin to 41.9 ± 19.7, 45.3 ± 16.1, 40.1 ± 15.3 and 39.2 ± 2.91 IU/L respectively compared with the value of paracetamol treatment, P < 0.01.
Effect on serum total bilirubin
The serum total bilirubin in the control group was 0.3 ± 0.14 mg/dl which was significantly increased by paracetamol treatment to 0.79 ± 0.56 mg/dl, P < 0.02. The level of serum total bilirubin then decreased to 0.31 ± 0.22, 0.3 ± 0.15, 0.3 ± 0.07 and 0.34 ± 0.14 mg/dl by carvedilol, prazosin, metoprolol, and the combination prazosin and metoprolol, respectively, P < 0.03 [Table 1].
Effect of Treatments on Malondialdehyde Level
Effect on serum malondialdehyde level
Serum level of MDA was significantly increased to 0.5 ± 0.29 μmol/l in the group treated with paracetamol compared with 0.2 ± 0.03 μmol/l of the control group, P < 0.05. Treatment with carvedilol prior to paracetamol reduced MDA level toward the control value from 0.5 ± 0.29 μmol/l in paracetamol-treated group to 0.2 ± 0.1 μmol/l in carvedilol treated group, P < 0.05. Treatment with prazosin before paracetamol reduced MDA level to 0.21 ± 0.05 μmol/l which was significantly lower than MDA level in rabbits treated with paracetamol, P < 0.05. Similar to prazosin, the combination of prazosin and metoprolol reduced elevated MDA level by paracetamol to 0.23 ± 0.09 μmol/l, P < 0.05. While treatment with metoprolol alone slightly and insignificantly reduced elevated serum MDA level by paracetamol to 0.36 ± 0.29 μmol/l. These data are presented in [Table 2].
|Table 2: Effect of adrenergic blockers on MDA and GSH in serum and liver homogenate in paracetamol-induced hepatotoxicity in rabbits|
Click here to view
Effect on malondialdehyde level in liver homogenate
The mean control value of MDA in liver homogenate was 2206 ± 580 nmol/g, which was significantly increased to 3958 ± 1016 nmol/g in the group of rabbits treated with paracetamol, P < 0.01.Treatment with carvedilol, prazosin and the combination prazosin and metoprolol before paracetamol has resulted in a significant reduction in the MDA level in liver homogenate to 2113 ± 567, 2247 ± 972, 2356 ± 935 nmol/g respectively. These values were significantly lower than 3958 ± 1016 nmol/g in the paracetamol treated group, P < 0.01. The level of MDA in liver homogenate in the group treated with metoprolol before paracetamol was to 3242 ± 766 nmol/g which was lower but did not achieve statistical significance from that of paracetamol treated group [Table 2].
Effect of Treatments on Glutathione Level
Effect on serum glutathione level
Serum GSH was 19.9 ± 10.9 nmol/ml in the control group which was significantly reduced to 10.5 ± 4.03 nmol/ml by paracetamol treatment, P < 0.03. In the group of rabbits treated with carvedilol before paracetamol, serum GSH increased to 19.1 ± 12.6 nmol/ml. In prazosin and prazosin plus metoprolol treatment before paracetamol, the level of S. GSH was significantly increased to 30.1 ± 8.19, 23.5 ± 10 nmol/ml respectively, P < 0.01. The level of serum GSH with metoprolol treatment before paracetamol was 12.4 ± 2.38 nmol/ml, which was slightly but insignificantly higher than. GSH level produced by paracetamol. These results are presented in [Table 2].
Effect on glutathione level in liver homogenate
The mean GSH level in liver homogenate of the control group was 9.77 ± 3.68 nmol/ml, which was insignificantly reduced by paracetamol to 7.84 ± 2.4 nmol/ml. The levels of GSH in liver homogenate in rabbits treated with carvedilol, prazosin, metoprolol and prazosin plus metoprolol when given before paracetamol were 9.51 ± 2.29, 8.94 ± 0.37, 9.27 ± 0.56 and 9.23 ± 0.64 nmol/ml respectively. These treatments did not achieve statistical differences compared with that of paracetamol treatment [Table 2].
| » Discussion|| |
Paracetamol is a widely used nonprescription analgesic and antipyretic drug. Among users, patients suffering from high blood pressure, migraine, myocardial infarction, congestive heart failure and thyrotoxicosis that may frequently and chronically use paracetamol to treat headache or ill-defined pain associated with these diseases. Beta-blockers, from the other hand, may concomitantly be prescribed for these patients as principal therapeutic drugs or as prophylactic, and paracetamol may present its self as a drug, which endanger liver function since it has a liver-damaging potential. Administration of paracetamol in the present study leads to elevation of MDA levels in serum and liver homogenate, suggesting provoked lipid peroxidation leading to tissue damage and failure of endogenous antioxidant defense. The serum level of AST and ALT were significantly elevated in paracetamol treated rabbits compared with the control group. This elevation is attributed to damaged liver cells since these enzymes are located in the cytosol and released into the blood following liver damage.  In few studies in the animal model, adrenergic blocker drugs were reported to have some protective effect against paracetamol toxicity. , and in one study adrenergic blockers were found protective against carbon tetrachloride hepatotoxicity.  In the present study carvedilol, a beta blocker, prazosin, an alpha blocker, metoprolol and prazosin combination were used in a rabbit model of hepatotoxicity induced by paracetamol. Adrenergic blockers used at these doses reduced paracetamol hepatotoxicity at varying degrees. On histopathological examination, prazosin treatment has prevented hepatotoxicity in five rabbits and liver sections in these rabbits appeared completely normal. These changes were paralleled with marked reduction in serum AST, ALT, ALP and total bilirubin. These findings are in agreement with the results of Randle et al.  The mechanism behind the hepatoprotection of prazosin is not well defined, however, marked reduction in MDA levels both in serum and in liver homogenate, with highly significant increase in serum GSH may suggest antioxidant mechanism as an important factor, and a hepatoprotection mechanism related to α1 -Adrenoceptor antagonism remains to be clarified. α1 -adrenoceptor blockers completely prevent erythrocytes accumulation within hepatic sinusoids and reduce hepatic perfusion caused by elevated circulating catecholamine associated with paracetamol toxicity. The ability of prazosin in preventing vasoconstriction and lowering portal pressure and improving liver perfusion through a reduction in intra-hepatic vascular resistance  would help maintain an adequate blood flow to the liver during xenobiotic bioactivation, hence participating in hepatoprotection. Prazosin has no antiinflammatory action, but it prevents inflammation accompanied by paracetamol toxicity through interrupting the earliest stages of this toxicity.  Carvedilol was selected for this study for its antioxidant properties and for its activity in inhibiting lipid peroxidation.  Similar to prazosin, treatment of rabbits with carvedilol 1 h before paracetamol administration significantly inhibited the hepatotoxicity of paracetamol to an extent less than that of prazosin. Hepatotoxicity of paracetamol was not affected by metoprolol compared to prazosin or carvedilol, and still features of sinusoidal dilatation with mild inflammation and hydropic degeneration is seen in histopathological examination. The presence of histopathological sings of paracetamol toxicity in the presence of metoprolol may, in part, reflect lacking of antioxidant activity of metoprolol,  or a result of drug interaction between metoprolol with paracetamol on the liver. It is worth mentioning that metoprolol, although rare, occasionally having some toxicity on the liver, characterized by hydropic degeneration.  The combination of metoprolol with prazosin produced a better effect on hepatotoxicity of paracetamol, but some features of toxicity still exist. These liver changes were mild, but not completely ameliorated. The combination of metoprolol and prazosin favorably corrected the rise in MDA produced by paracetamol toxicity and significantly corrected depletion of GSH, which is highly in favor of involvement of antioxidant mechanism in hepatoprotection by the addition of prazosin. It can be speculated that paracetamol liver toxicity is more pronounced in diseases accompanied by high catecholamine level such as congestive heart failure , or thyrotoxicosis.  Paracetamol in theses disease is expected to produce liver toxicity at therapeutic doses and that the use of adrenergic blockers may be beneficial in minimizing the toxicity of paracetamol. It can be concluded that adrenergic blockers are not the specific antidotes for paracetamol hepatotoxicity, however, concomitant use with paracetamol may minimize such toxicity. Carvedilol and prazosin have hepatoprotective effects in paracetamol-induced hepatotoxicity, combination of prazosin and metoprolol have moderate, and metoprolol has little hepatoprotective potential.
| » References|| |
Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al.
Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005;42:1364-72.
Randle LE, Sathish JG, Kitteringham NR, Macdonald I, Williams DP, Park BK. alpha (1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. Br J Pharmacol 2008;153:820-30.
Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
Cigremis Y, Turel H, Adiguzel K, Akgoz M, Kart A, Karaman M, et al.
The effects of acute acetaminophen toxicity on hepatic mRNA expression of SOD, CAT, GSH-Px, and levels of peroxynitrite, nitric oxide, reduced glutathione, and malondialdehyde in rabbit. Mol Cell Biochem 2009;323:31-8.
Ronsein GE, Guidi DB, Benassi JC, Filho DW, Pedrosa RC, Pedrosa RC. Cytoprotective effects of carvedilol against oxygen free radical generation in rat liver. Redox Rep 2005;10:131-7.
Antelava NA, Gabuniia LIu, Gambashidze KG, Pkhaladze NG, Arziani BA. Influence of different type beta-adrenoblockers on functional state of liver at paracetamol induced toxic hepatitis in experiment. Georgian Med News 2009;64-8.
Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: Antifibrotic effects of carvedilol in chronic carbon tetrachloride-induced liver damage. Toxicol Appl Pharmacol 2012;261:292-9.
Albillos A, Lledó JL, Rossi I, Pérez-Páramo M, Tabuenca MJ, Bañares R, et al.
Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995;109:1257-65.
Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro
. J Cardiovasc Pharmacol 2000;36:277-81.
Larrey D, Henrion J, Heller F, Babany G, Degott C, Pessayre D, et al.
Metoprolol-induced hepatitis: Rechallenge and drug oxidation phenotyping. Ann Intern Med 1988;108:67-8.
Mancia G. Sympathetic activation in congestive heart failure. Eur Heart J 1990;11 Suppl A: 3-11.
Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol 2011;20:135-42.
Nilsson OR, Karlberg BE. Thyroid hormones and the adrenergic nervous system. Acta Med Scand Suppl 1983;672:27-32.
[Figure 1], [Figure 2]
[Table 1], [Table 2]